Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468247 | 0.80 | MAPT (0.35) | MAPTHTR2BALDH1A1 | |
| SCHEMBL1051061 | 0.79 | MAPT (0.40) | MAPTHTR2BALDH1A1 | |
| SCHEMBL2438716 | 0.79 | MAPT (0.41) | MAPTHTR2BALDH1A1 | |
| SCHEMBL9381730 | 0.77 | MAPT (0.36) | MAPTHTR2BALDH1A1 | |
| SCHEMBL9568876 | 0.75 | HTR2B (0.40) | MAPTHTR2BALDH1A1 | |
| SCHEMBL16742562 | 0.74 | MAPT (0.45) | MAPTHTR2BALDH1A1 | |
| SCHEMBL3549501 | 0.72 | SMN1; SMN2 (0.41) | MAPT | |
| SCHEMBL10771875 | 0.71 | — | — | |
| SCHEMBL13999711 | 0.70 | MAPT (0.39) | MAPTHTR2BALDH1A1 | |
| SCHEMBL20130304 | 0.70 | HTR2B (0.35) | MAPTHTR2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | MAPT 1330/4885HTR2B 2017/4885ALDH1A1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.